We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Understanding Tumor Cell Metabolism Key to Personalized Chemotherapy

By LabMedica International staff writers
Posted on 04 May 2011
Cancer researchers have coined the term "Metabolo-Genomics” to define a new approach to personalized cancer medicine, which incorporates features of both cell metabolism and gene transcriptional profiling.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) used this approach to study the effect of cancer cell metabolism on clinical outcome. More...
They had previously shown that lactate and ketone utilization in cancer cells promoted the formation of a "cancer stem cell” phenotype, resulting in significant decreases in patient survival.

In the current study, human breast cancer cells (MCF7) were cultured with lactate or ketones, and then subjected to transcriptional analysis (exon-array). Results published in the April 15, 2011, online edition of the journal Cell Cycle revealed that treatment with these high-energy metabolites increased the transcriptional expression of gene profiles normally associated with "stemness,” including genes upregulated in embryonic stem (ES) cells. Similarly, the results showed that lactate and ketones promoted the growth of bonafide ES cells, providing functional validation. The lactate- and ketone-induced "gene signatures” were able to predict poor clinical outcome (including recurrence and metastasis) in a cohort of human breast cancer patients.

"Tumors that are using the body's own nutrients (lactate and ketones) as "fuel” have a poorer outcome for patient survival, a behavior that now can be used to predict if a patient is at a high-risk for recurrence or metastasis,” said senior author Dr. Michael P. Lisanti, professor of cancer biology at Thomas Jefferson University. "This is getting to the heart of personalized cancer medicine. Now, we have identified a panel of biomarkers that directly links cancer metabolism with targeted cancer therapy.”

"Just by feeding cancer cells a particular energy-rich diet, it changes their character, without introducing mutations or altering their genetic profile,” Dr. Lisanti said. "We have only fed them high energy nutrients that help them to use their mitochondria, and this changes their transcriptional profile. It is a new biomarker for "lethal” cancers that we can now treat with the right drugs, such as the antioxidant metformin.”

Related Links:
Thomas Jefferson University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.